Skip to main content
. 2023 Feb;4(2):e113–e125. doi: 10.1016/S2666-5247(22)00303-2

Table 1.

Data on the preclinical and clinical development of vaccines for pathogens in three categories

Preclinical Phase 1 Phase 2 Phase 3
Group A
Streptococcus pneumoniae 17 4 8 4
Haemophilus influenzae type b 3 1 0 3
Salmonella enterica serotype Typhi 8 1 1 3
Mycobacterium tuberculosis 20 2 7 4
Group B
Extra-intestinal pathogenic Escherichia coli 4 1 2 1
Clostridioides difficile 5 1 0 1
Salmonella enterica serotype Paratyphi 4 1 1 1
Neisseria gonorrhoeae 2 0 0 1
Group C
Enterotoxigenic E coli 10 4 2 0
Shigella spp 10 6 2 0
Shigella flexneri .. 3 1 0
Shigella sonnei .. 0 1 0
S flexneri and S sonnei .. 3 0 0
Non-typhoidal Salmonella 5 1 0 0
Klebsiella pneumoniae 5 1 0 0
Campylobacter spp 4 0 0 0

Group A are pathogens with vaccines that are already licensed. Group B are pathogens with vaccines in late-stage clinical trials with high development feasibility. Group C are pathogens with vaccine candidates either in early clinical trials or with moderate to high feasibility of vaccine development.